Uridine relieves MSCs and chondrocyte senescence in vitvo and exhibits the potential to treat osteoarthritis in vivo. Issue 1 (2nd January 2022)

• Record Type: Journal Article
• Authors: Ye, Jia; Jin, Zhihui; Chen, Sen; Guo, Weichun
• Is Part Of: Cell cycle. Volume 21:Issue 1(2022)
• Page Start: 33
• Page End: 48
• Publication Date: 2022-01-02
• Subjects: Uridine -- chondrocyte cell line -- MSC -- aging -- osteoarthritis (OA); Cell cycle -- Periodicals; 571.84377
• DOI: 10.1080/15384101.2021.2010170
• Languages: English
• ISSNs: 1538-4101

Abstract

ABSTRACT: Osteoarthritis (OA) is a degenerative disease of extremely high incidence in the elderly. Therefore, anti-aging may be an important prerequisite for treating OA. The senescence of chondrocytes and mesenchymal stem cells (MSCs) is one of the important factors that causes OA. Here, the effect of uridine (which is a functional food derived from plants or animals) on senescence of chondrocytes and MSCs was evaluated in in vivo and in vitro experiments. For this, we established the senescence model of chondrocyte and MSCs in vitro, and established the OA model in vivo, and a series of experiments (such as CLSM, ELISA, Western blot, etc.) were conducted to evaluate the effect of uridine on chondrocyte and MSCs senescence. The results showed that uridine could alleviate chondrocyte and MSCs senescence in vitro by evaluating a series of aging markers. Furthermore, uridine could also relieve OA in vivo . In summary, in the present work, we found that uridine can alleviate chondrocyte and MSCs senescence in in vitro and in vivo experiments. Uridine has shown great potential in the treatment of OA in vivo, suggesting that uridine could be used to treat and prevent OA induced by aging, and has potential clinical applications in future.